Julie Helft
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Julie Helft has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
- Federica Benvenuti
Cellular Immunology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy
13 shared publications - Yoann Missolo-Koussou
Department of Translational Research, PSL University, Institut Curie Research Center, Paris, France
13 shared publications - William Vermi
Department of Molecular and Translational Medicine University of Brescia Brescia Italy
12 shared publications - Francesco Missale
IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy
11 shared publications - Irene Pezzali
Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
11 shared publications - Laura Ardighieri
10Department of Pathology, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy
11 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Springer Nature in Research Square
CD4+ T cell–T cell interactions preserve clonal diversity to recognize antigen variants
Recruitment of diverse antigen-specific T-cell clones is essential for effective CD4+ T cell immunity, enhancing the robustness of responses to antigenic variation. However, because CD4+ T cell proliferation requires repeated antigen encounter1,2 and peptide–MHC-II complexes are long-lived in vivo3, sustained stimulation is expected to preferentially expand the clones with the highest TCR avidity4, thereby reducing clonal diversity. Yet, CD4+ T cell responses in vivo remain remarkably diverse5–8. The mechanisms that preserve clonal diversity during T cell expansion remain poorly understood. Here, we provide in vivo evidence for antigen-specific CD4+ T cell–T cell (T–T) contacts and demonstrate that SOCS1-dependent inhibition of antigen-experienced CD4+ T cell proliferation preserves repertoire diversity during an ongoing immune response. Mathematical modelling predicted that such T–T contacts can maintain a diverse response by limiting preferential expansion of the most avid clones. Inducible SOCS1 disruption validated this prediction by converting the response into an oligoclonal expansion dominated by a few high-avidity clones. Large-scale experimental measurements of TCR avidity and antigen-variant recognition showed that wild-type repertoires retain clones spanning a broad avidity range and complementary cross-reactivity profiles. A sequence-based machine-learning model extended these measurements to whole repertoires, revealing broader coverage of antigenic variation in wild-type than in SOCS1-deficient responses, a prediction confirmed experimentally by recall responses to antigen variants. Simulations further showed that the size of wild-type expanded repertoires lies within the range predicted to achieve near-optimal coverage of antigenic variation. Thus, antigen-specific T cell–T cell interactions and SOCS1 signaling control TCR diversity and improve the adaptability of CD4+ T cell immunity to antigenic variation.
- 6 October 2026
- Published by Springer Nature in Research Square
Open AccessCD4+ T cell–T cell interactions preserve clonal diversity to recognize antigen variants
Recruitment of diverse antigen-specific T-cell clones is essential for effective CD4+ T cell immunity, enhancing the robustness of responses to antigenic variation. However, because CD4+ T cell proliferation requires repeated antigen encounter1,2 and peptide–MHC-II complexes are long-lived in vivo3, sustained stimulation is expected to preferentially expand the clones with the highest TCR avidity4, thereby reducing clonal diversity. Yet, CD4+ T cell responses in vivo remain remarkably diverse5–8. The mechanisms that preserve clonal diversity during T cell expansion remain poorly understood. Here, we provide in vivo evidence for antigen-specific CD4+ T cell–T cell (T–T) contacts and demonstrate that SOCS1-dependent inhibition of antigen-experienced CD4+ T cell proliferation preserves repertoire diversity during an ongoing immune response. Mathematical modelling predicted that such T–T contacts can maintain a diverse response by limiting preferential expansion of the most avid clones. Inducible SOCS1 disruption validated this prediction by converting the response into an oligoclonal expansion dominated by a few high-avidity clones. Large-scale experimental measurements of TCR avidity and antigen-variant recognition showed that wild-type repertoires retain clones spanning a broad avidity range and complementary cross-reactivity profiles. A sequence-based machine-learning model extended these measurements to whole repertoires, revealing broader coverage of antigenic variation in wild-type than in SOCS1-deficient responses, a prediction confirmed experimentally by recall responses to antigen variants. Simulations further showed that the size of wild-type expanded repertoires lies within the range predicted to achieve near-optimal coverage of antigenic variation. Thus, antigen-specific T cell–T cell interactions and SOCS1 signaling control TCR diversity and improve the adaptability of CD4+ T cell immunity to antigenic variation.
- Open Access
- 18 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Distinct migratory dendritic cell subsets cooperate to prime tissue-resident memory-like CD8⁺ T cells in mouse tumors
Tumor-infiltrating tissue-resident memory (TRM)-like CD8+ T cells correlate with positive prognosis and better responses to cancer immunotherapy, yet the mechanisms underlying their specification remain ill-understood. Here, we use the KP (KrasG12D, p53-/-) mouse model of lung adenocarcinoma to investigate how different dendritic cell (DC) subsets shape tumor-specific CD8+ T cell responses. Selective ablation of XCR1+ DC1s or IRF4-dependent CD11b+ DC2s reveal that DC1s, but not DC2s, are required for the generation of tumor-infiltrating effector and exhausted CD8+ T cells. By contrast, both migratory DC1s and migratory DC2s contribute to the specification of CD103+CD69+ TRM-like CD8+ T cells in tumor-draining lymph nodes. Mechanistically, low peptide/MHC-I density on migratory DC2s favors TGFβ-dependent TRM differentiation, while high peptide/MHC-I density on DC1s promote proliferative expansion of TRM-like cells; in addition, IL-12 secreted by DC1s enhances CXCR6 expression. Together, our findings uncover complementary functions of migratory DC subsets in shaping anti-tumor TRM-like CD8+ T cell responses, and also implicate targeting multiple DC subsets for optimizing cancer immunotherapy.
- 18 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDistinct migratory dendritic cell subsets cooperate to prime tissue-resident memory-like CD8⁺ T cells in mouse tumors
Tumor-infiltrating tissue-resident memory (TRM)-like CD8+ T cells correlate with positive prognosis and better responses to cancer immunotherapy, yet the mechanisms underlying their specification remain ill-understood. Here, we use the KP (KrasG12D, p53-/-) mouse model of lung adenocarcinoma to investigate how different dendritic cell (DC) subsets shape tumor-specific CD8+ T cell responses. Selective ablation of XCR1+ DC1s or IRF4-dependent CD11b+ DC2s reveal that DC1s, but not DC2s, are required for the generation of tumor-infiltrating effector and exhausted CD8+ T cells. By contrast, both migratory DC1s and migratory DC2s contribute to the specification of CD103+CD69+ TRM-like CD8+ T cells in tumor-draining lymph nodes. Mechanistically, low peptide/MHC-I density on migratory DC2s favors TGFβ-dependent TRM differentiation, while high peptide/MHC-I density on DC1s promote proliferative expansion of TRM-like cells; in addition, IL-12 secreted by DC1s enhances CXCR6 expression. Together, our findings uncover complementary functions of migratory DC subsets in shaping anti-tumor TRM-like CD8+ T cell responses, and also implicate targeting multiple DC subsets for optimizing cancer immunotherapy.
- Open Access
- 9 April 2026
- Published by Springer Nature in Research Square
XCR1+ and CD11b+ migratory dendritic cells cooperate for the cross-priming of intratumoral CD8+ T cells with a tissue-resident memory phenotype.
The composition and diversity of tumor-infiltrating CD8+ T cell populations have important consequences on the development of anti-tumor immunity. In a murine model of lung cancer, we have addressed the role of dendritic cell subsets on the generation of various types of tumor-infiltrating CD8+ T cells. We show that CD44+PD1- effector and PD1+TIM3+ exhausted, tumor-infiltrating CD8+ T cells require XCR1+ DC1s but not IRF4-dependent CD11b+ DC2s. By contrast, immunotherapy responsive CD103+CXCR6+ TRM-like, tumor-infiltrating CD8+ T cells require both DC1s and DC2s. The same requirement is found in tumor-draining lymph nodes where we identify CD103+CXCR6+ TRM-like precursors that are dependent on both XCR1+ DC1s and CD11b+, migratory DC2s. Mechanistically, we evidence that both types of migratory DCs cooperate. Mild TCR triggering by low MHCI-peptide density at the surface of cross-presenting migratory DC2s and low IL-12 support TGF-β -dependent TRM specification in lymph nodes. High TCR triggering and high MHCI-peptide density at the surface of cross-presenting migratory DC1s and high IL-12 support proliferative expansion and CXCR6 acquisition. Altogether, these findings highlight the induction of intratumoral TRM-like cells under the collective aegis of multiple DCs subsets within tumor-draining lymph nodes reconciliating TRM phenotype instruction with proliferative expansion.
- 9 April 2026
- Published by Springer Nature in Research Square
Open AccessXCR1+ and CD11b+ migratory dendritic cells cooperate for the cross-priming of intratumoral CD8+ T cells with a tissue-resident memory phenotype.
The composition and diversity of tumor-infiltrating CD8+ T cell populations have important consequences on the development of anti-tumor immunity. In a murine model of lung cancer, we have addressed the role of dendritic cell subsets on the generation of various types of tumor-infiltrating CD8+ T cells. We show that CD44+PD1- effector and PD1+TIM3+ exhausted, tumor-infiltrating CD8+ T cells require XCR1+ DC1s but not IRF4-dependent CD11b+ DC2s. By contrast, immunotherapy responsive CD103+CXCR6+ TRM-like, tumor-infiltrating CD8+ T cells require both DC1s and DC2s. The same requirement is found in tumor-draining lymph nodes where we identify CD103+CXCR6+ TRM-like precursors that are dependent on both XCR1+ DC1s and CD11b+, migratory DC2s. Mechanistically, we evidence that both types of migratory DCs cooperate. Mild TCR triggering by low MHCI-peptide density at the surface of cross-presenting migratory DC2s and low IL-12 support TGF-β -dependent TRM specification in lymph nodes. High TCR triggering and high MHCI-peptide density at the surface of cross-presenting migratory DC1s and high IL-12 support proliferative expansion and CXCR6 acquisition. Altogether, these findings highlight the induction of intratumoral TRM-like cells under the collective aegis of multiple DCs subsets within tumor-draining lymph nodes reconciliating TRM phenotype instruction with proliferative expansion.
- Open Access
- 30 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Intratumoral delivery of FLT3L with CXCR3/CCR5 ligands promotes XCR1+ cDC1 infiltration and activates anti-tumor immunity
Tumor infiltration by XCR1⁺ conventional dendritic cells (cDC1) correlates strongly with favorable prognosis and improved responses to immunotherapy. Yet, tumor-driven immunosuppressive programs restrict efficient cDC1 recruitment, highlighting the need for strategies to increase cDC1 access to the tumor microenvironment. Here, we establish a proof-of-concept cell-based immunotherapy that enhances the infiltration of circulating cDC1 progenitors and supports their local expansion. Intratumoral engraftment of autologous mesenchymal stromal cells engineered to express membrane bound FLT3L promotes cDC1 recruitment when combined with poly(I:C). We identify poly(I:C)-induced CXCL9 and CCL5 as essential chemokines controlling intratumoral cDC1 infiltration. Stromal cell–mediated local delivery of FLT3L together with CXCL9 and CCL5 is sufficient to enhance cDC1 infiltration in mice or humanized mice settings. Finally, this approach activates antitumor immunity and partially overcomes resistance to immune checkpoint blockade. Collectively, our data support the therapeutic potential of expanding intratumoral cDC1s through local and sustained delivery of FLT3L, CXCL9, and CCL5.
- 30 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessIntratumoral delivery of FLT3L with CXCR3/CCR5 ligands promotes XCR1+ cDC1 infiltration and activates anti-tumor immunity
Tumor infiltration by XCR1⁺ conventional dendritic cells (cDC1) correlates strongly with favorable prognosis and improved responses to immunotherapy. Yet, tumor-driven immunosuppressive programs restrict efficient cDC1 recruitment, highlighting the need for strategies to increase cDC1 access to the tumor microenvironment. Here, we establish a proof-of-concept cell-based immunotherapy that enhances the infiltration of circulating cDC1 progenitors and supports their local expansion. Intratumoral engraftment of autologous mesenchymal stromal cells engineered to express membrane bound FLT3L promotes cDC1 recruitment when combined with poly(I:C). We identify poly(I:C)-induced CXCL9 and CCL5 as essential chemokines controlling intratumoral cDC1 infiltration. Stromal cell–mediated local delivery of FLT3L together with CXCL9 and CCL5 is sufficient to enhance cDC1 infiltration in mice or humanized mice settings. Finally, this approach activates antitumor immunity and partially overcomes resistance to immune checkpoint blockade. Collectively, our data support the therapeutic potential of expanding intratumoral cDC1s through local and sustained delivery of FLT3L, CXCL9, and CCL5.
- Open Access
Intratumoral delivery of FLT3L with CXCR3/CCR5 ligands promotes XCR1 + cDC1 infiltration and activates anti-tumor immunity
Tumor infiltration by dendritic cells (DCs) has been identified as a biomarker associated with favorable outcomes and improved responses to immunotherapies by T cell immune checkpoint blockade. However, tumor induced immunosuppressive pathways contrive efficient DC infiltration. This calls for the development of DC-targeted interventions purposed to stimulate DC infiltration and local expansion. Here we deliver a proof-of-concept for a cell-based immunotherapeutic approach promoting circulating DC progenitors infiltration in the tumor together with their local expansion. We report that engraftment of autologous mesenchymal stromal cells engineered to express the membrane bound form of FLT3L (eMSC-FLT3L) uniquely induce DC infiltration, T cells activation and anti-tumor immunity, when combined with an adjuvant like the poly(I:C) double stranded RNA mimic. Mechanistic experiments demonstrate that poly(I:C)-induced CXCR3 and CCR5 ligands (CXCL9, CCL5) are required for intra-tumoral DC and T cell recruitment and for the therapeutic effect of eMSC-FLT3L + poly(I:C) immunotherapy. Stromal cell-based delivery of CXCL9 and CCL5, together with FLT3L, by-passes the requirement for poly(I:C) agonist and is sufficient to induce T cell and DC recruitment within tumors. These findings are transferrable to human settings as we show that eMSCs-FLT3L-CXCL9-CCL5 stimulate tissue infiltration by human XCR1+ DC1s in mice harboring a ‘Human Immune System’ (HIS mice). Lastly, we report that engraftment of eMSC-FLT3L-CXCL9-CCL5 in the tumor induces anti-tumor immunity and partially overcomes resistance to immune checkpoint blockade. Altogether, these data support the therapeutic potential of expanding intra-tumoral DC1s using a continuous and local source of FLT3L, CXCL9 and CCL5. One sentence summary Intra-tumoral delivery of FLT3L synergizes with CXCL9 and CCL5 to activate the expansion of intra-tumoral DCs.
Open AccessIntratumoral delivery of FLT3L with CXCR3/CCR5 ligands promotes XCR1 + cDC1 infiltration and activates anti-tumor immunity
Tumor infiltration by dendritic cells (DCs) has been identified as a biomarker associated with favorable outcomes and improved responses to immunotherapies by T cell immune checkpoint blockade. However, tumor induced immunosuppressive pathways contrive efficient DC infiltration. This calls for the development of DC-targeted interventions purposed to stimulate DC infiltration and local expansion. Here we deliver a proof-of-concept for a cell-based immunotherapeutic approach promoting circulating DC progenitors infiltration in the tumor together with their local expansion. We report that engraftment of autologous mesenchymal stromal cells engineered to express the membrane bound form of FLT3L (eMSC-FLT3L) uniquely induce DC infiltration, T cells activation and anti-tumor immunity, when combined with an adjuvant like the poly(I:C) double stranded RNA mimic. Mechanistic experiments demonstrate that poly(I:C)-induced CXCR3 and CCR5 ligands (CXCL9, CCL5) are required for intra-tumoral DC and T cell recruitment and for the therapeutic effect of eMSC-FLT3L + poly(I:C) immunotherapy. Stromal cell-based delivery of CXCL9 and CCL5, together with FLT3L, by-passes the requirement for poly(I:C) agonist and is sufficient to induce T cell and DC recruitment within tumors. These findings are transferrable to human settings as we show that eMSCs-FLT3L-CXCL9-CCL5 stimulate tissue infiltration by human XCR1+ DC1s in mice harboring a ‘Human Immune System’ (HIS mice). Lastly, we report that engraftment of eMSC-FLT3L-CXCL9-CCL5 in the tumor induces anti-tumor immunity and partially overcomes resistance to immune checkpoint blockade. Altogether, these data support the therapeutic potential of expanding intra-tumoral DC1s using a continuous and local source of FLT3L, CXCL9 and CCL5. One sentence summary Intra-tumoral delivery of FLT3L synergizes with CXCL9 and CCL5 to activate the expansion of intra-tumoral DCs.
- 30 November 2023
- Published by Springer Nature in Nature Cell Biology
- Vol. 25 (12) , 1736-1745
Breast cancer remotely imposes a myeloid bias on haematopoietic stem cells by reprogramming the bone marrow niche
Myeloid cell infiltration of solid tumours generally associates with poor patient prognosis and disease severity1,2,3,4,5,6,7,8,9,10,11,12,13. Therefore, understanding the regulation of myeloid cell differentiation during cancer is crucial to counteract their pro-tumourigenic role. Bone marrow (BM) haematopoiesis is a tightly regulated process for the production of all immune cells in accordance to tissue needs14. Myeloid cells differentiate during haematopoiesis from multipotent haematopoietic stem and progenitor cells (HSPCs)15,16,17. HSPCs can sense inflammatory signals from the periphery during infections18,19,20,21 or inflammatory disorders22,23,24,25,26,27. In these settings, HSPC expansion is associated with increased myeloid differentiation28,29. During carcinogenesis, the elevation of haematopoietic growth factors supports the expansion and differentiation of committed myeloid progenitors5,30. However, it is unclear whether cancer-related inflammation also triggers demand-adapted haematopoiesis at the level of multipotent HSPCs. In the BM, HSPCs reside within the haematopoietic niche which delivers HSC maintenance and differentiation cues31,32,33,34,35. Mesenchymal stem cells (MSCs) are a major cellular component of the BM niche and contribute to HSC homeostasis36,37,38,39,40,41. Modifications of MSCs in systemic disorders have been associated with HSC differentiation towards myeloid cells22,42. It is unknown if MSCs are regulated in the context of solid tumours and if their myeloid supportive activity is impacted by cancer-induced systemic changes. Here, using unbiased transcriptomic analysis and in situ imaging of HSCs and the BM niche during breast cancer, we show that both HSCs and MSCs are transcriptionally and spatially modified. We demonstrate that breast tumour can distantly remodel the cellular cross-talks in the BM niche leading to increased myelopoiesis.
- 30 November 2023
- Published by Springer Nature in Nature Cell Biology
- Vol. 25 (12) , 1736-1745
Breast cancer remotely imposes a myeloid bias on haematopoietic stem cells by reprogramming the bone marrow niche
Myeloid cell infiltration of solid tumours generally associates with poor patient prognosis and disease severity1,2,3,4,5,6,7,8,9,10,11,12,13. Therefore, understanding the regulation of myeloid cell differentiation during cancer is crucial to counteract their pro-tumourigenic role. Bone marrow (BM) haematopoiesis is a tightly regulated process for the production of all immune cells in accordance to tissue needs14. Myeloid cells differentiate during haematopoiesis from multipotent haematopoietic stem and progenitor cells (HSPCs)15,16,17. HSPCs can sense inflammatory signals from the periphery during infections18,19,20,21 or inflammatory disorders22,23,24,25,26,27. In these settings, HSPC expansion is associated with increased myeloid differentiation28,29. During carcinogenesis, the elevation of haematopoietic growth factors supports the expansion and differentiation of committed myeloid progenitors5,30. However, it is unclear whether cancer-related inflammation also triggers demand-adapted haematopoiesis at the level of multipotent HSPCs. In the BM, HSPCs reside within the haematopoietic niche which delivers HSC maintenance and differentiation cues31,32,33,34,35. Mesenchymal stem cells (MSCs) are a major cellular component of the BM niche and contribute to HSC homeostasis36,37,38,39,40,41. Modifications of MSCs in systemic disorders have been associated with HSC differentiation towards myeloid cells22,42. It is unknown if MSCs are regulated in the context of solid tumours and if their myeloid supportive activity is impacted by cancer-induced systemic changes. Here, using unbiased transcriptomic analysis and in situ imaging of HSCs and the BM niche during breast cancer, we show that both HSCs and MSCs are transcriptionally and spatially modified. We demonstrate that breast tumour can distantly remodel the cellular cross-talks in the BM niche leading to increased myelopoiesis.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types
Supplementary Table from A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types
Supplementary Table from A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types
Supplementary Data from A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types
Supplementary Data from A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types
Supplementary Table from A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types
Supplementary Table from A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types
TIM4 has previously been associated with antitumor immunity, yet the pattern of expression and the function of this receptor across human cancer tissues remain poorly explored. Here we combined extensive immunolabeling of human tissues with in silico analysis of pan-cancer transcriptomic data sets to explore the clinical significance of TIM4 expression. Our results unveil that TIM4 is expressed on a fraction of cavity macrophages (CATIM4+MΦ) of carcinoma patients. Moreover, we uncover a high expression of TIM4 on macrophages of the T-cell zone of the carcinoma-associated tertiary lymphoid structures (TLSTIM4+MΦ). In silico analysis of a pan-cancer data set revealed a positive correlation between TIM4 expression and markers of B cells, effector CD8+ T cells, and a 12-chemokine signature defining tertiary lymphoid structure. In addition, TLSTIM4+MΦ were enriched in cancers displaying microsatellite instability and high CD8+ T-cell infiltration, confirming their association with immune-reactive tumors. Both CATIM4+MΦ and TLSTIM4+MΦ express FOLR2, a marker of tissue-resident MΦ. However, CATIM4+MΦ had a higher expression of the immunosuppressive molecules TREM2, IL10, and TGFβ as compared with TLSTIM4+MΦ. By analyzing a scRNA sequence data set of tumor-associated myeloid cells, we identified two TIM4+FOLR2+ clusters coherent with CATIM4+MΦ and TLSTIM4+MΦ. We defined specific gene signatures for each subset and found that the CATIM4+ MΦ signature was associated with worse patient survival. In contrast, TLSTIM4+MΦ gene signature positively correlates with a better prognosis. Together, these data illustrate that TIM4 marks two distinct macrophage populations with distinct phenotypes and tissue localization and that may have opposing roles in tumor immunity.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types
TIM4 has previously been associated with antitumor immunity, yet the pattern of expression and the function of this receptor across human cancer tissues remain poorly explored. Here we combined extensive immunolabeling of human tissues with in silico analysis of pan-cancer transcriptomic data sets to explore the clinical significance of TIM4 expression. Our results unveil that TIM4 is expressed on a fraction of cavity macrophages (CATIM4+MΦ) of carcinoma patients. Moreover, we uncover a high expression of TIM4 on macrophages of the T-cell zone of the carcinoma-associated tertiary lymphoid structures (TLSTIM4+MΦ). In silico analysis of a pan-cancer data set revealed a positive correlation between TIM4 expression and markers of B cells, effector CD8+ T cells, and a 12-chemokine signature defining tertiary lymphoid structure. In addition, TLSTIM4+MΦ were enriched in cancers displaying microsatellite instability and high CD8+ T-cell infiltration, confirming their association with immune-reactive tumors. Both CATIM4+MΦ and TLSTIM4+MΦ express FOLR2, a marker of tissue-resident MΦ. However, CATIM4+MΦ had a higher expression of the immunosuppressive molecules TREM2, IL10, and TGFβ as compared with TLSTIM4+MΦ. By analyzing a scRNA sequence data set of tumor-associated myeloid cells, we identified two TIM4+FOLR2+ clusters coherent with CATIM4+MΦ and TLSTIM4+MΦ. We defined specific gene signatures for each subset and found that the CATIM4+ MΦ signature was associated with worse patient survival. In contrast, TLSTIM4+MΦ gene signature positively correlates with a better prognosis. Together, these data illustrate that TIM4 marks two distinct macrophage populations with distinct phenotypes and tissue localization and that may have opposing roles in tumor immunity.